NCT03204019

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor

Conditions

• Pancreatic Neuroendocrine Tumor

Interventions

Type	Name	Description
DRUG	Tegafur and Temozolomide	Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
DRUG	Tegafur and Temozolomide combined with Thalidomide	Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)

Timeline

• Start date: 2016-10-01
• Primary completion: 2017-10-01
• Completion: 2018-09-01
• First posted: 2017-06-29
• Last updated: 2017-06-29

Locations

1 site across 1 country: China